Published in J Virol on October 01, 2004
Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29
Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res (2007) 1.64
Antiviral immune responses in the genital tract: clues for vaccines. Nat Rev Immunol (2010) 1.45
Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood (2006) 1.21
Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs. J Virol (2006) 1.20
Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J Virol (2007) 1.12
DNA vaccines delivered by human papillomavirus pseudovirions as a promising approach for generating antigen-specific CD8+ T cell immunity. Cell Biosci (2011) 1.11
Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J (2008) 1.04
Proteasome-independent major histocompatibility complex class I cross-presentation mediated by papaya mosaic virus-like particles leads to expansion of specific human T cells. J Virol (2006) 1.04
Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol (2005) 1.00
Toll-like receptor-independent triggering of dendritic cell maturation by viruses. J Virol (2006) 0.97
Expression of Toll-like receptors and their association with cytokine responses in peripheral blood mononuclear cells of children with acute rotavirus diarrhoea. Clin Exp Immunol (2006) 0.95
Gene expression patterns induced by HPV-16 L1 virus-like particles in leukocytes from vaccine recipients. J Immunol (2009) 0.93
Differential involvement of Th1 and Th17 in pathogenic autoimmune processes triggered by different TLR ligands. J Immunol (2013) 0.93
Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol (2010) 0.92
Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer (2011) 0.90
Local innate immune responses in the vaccine adjuvant-injected muscle. Clin Transl Immunology (2016) 0.89
Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles. Cancer Immunol Immunother (2010) 0.86
Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells. Mol Immunol (2009) 0.85
Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells. Oncotarget (2014) 0.85
Epinephrine-primed murine bone marrow-derived dendritic cells facilitate production of IL-17A and IL-4 but not IFN-γ by CD4+ T cells. Brain Behav Immun (2010) 0.84
Epigenetic modification of TLR4 promotes activation of NF-κB by regulating methyl-CpG-binding domain protein 2 and Sp1 in gastric cancer. Oncotarget (2016) 0.80
Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. Cytokine Growth Factor Rev (2013) 0.79
Evasion of Host Immune Defenses by Human Papillomavirus. Virus Res (2016) 0.77
MicroRNA-22 impairs anti-tumor ability of dendritic cells by targeting p38. PLoS One (2015) 0.77
Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination. Cell Biosci (2015) 0.76
Coupling Peptide Antigens to Virus-Like Particles or to Protein Carriers Influences the Th1/Th2 Polarity of the Resulting Immune Response. Vaccines (Basel) (2016) 0.75
MicroRNA-200c Promotes Suppressive Potential of Myeloid-Derived Suppressor Cells by Modulating PTEN and FOG2 Expression. PLoS One (2015) 0.75
Diversities of interaction of murine macrophages with three strains of Candida albicans represented by MyD88, CARD9 gene expressions and ROS, IL-10 and TNF-α secretion. Int J Clin Exp Med (2014) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med (2002) 10.58
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med (1999) 8.01
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 7.78
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med (2002) 5.70
Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med (1997) 5.56
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Interferons alpha and beta as immune regulators--a new look. Immunity (2001) 4.75
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol (2002) 4.12
Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med (1999) 3.64
Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell (2000) 3.44
Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol (2002) 3.37
The influence of antigen organization on B cell responsiveness. Science (1993) 3.32
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem (1999) 3.16
Murine retroviruses activate B cells via interaction with toll-like receptor 4. Proc Natl Acad Sci U S A (2002) 2.70
Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol (2001) 2.28
In the absence of IL-12, CD4(+) T cell responses to intracellular pathogens fail to default to a Th2 pattern and are host protective in an IL-10(-/-) setting. Immunity (2002) 2.23
Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol (1999) 1.91
Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J Virol (1998) 1.85
Chemokines: attractive mediators of the immune response. Semin Immunol (2003) 1.66
Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest (2001) 1.63
Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A (1998) 1.59
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol (2002) 1.48
Role of adapters in Toll-like receptor signalling. Biochem Soc Trans (2003) 1.47
Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol (2001) 1.46
CpG DNA induces self and cross-hyporesponsiveness of RAW264.7 cells in response to CpG DNA and lipopolysaccharide: alterations in IL-1 receptor-associated kinase expression. J Immunol (2003) 1.35
Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A (1999) 1.31
Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. J Biol Chem (2003) 1.27
A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis (2001) 1.20
L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology (1998) 1.15
Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol (2003) 1.12
Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol (2002) 1.12
Identification of the receptor binding domain of the mouse mammary tumor virus envelope protein. J Virol (2003) 1.11
Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol (2001) 1.07
Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol (2003) 1.03
Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine. Arch Med Res (2000) 0.90
Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem (1999) 0.88
Glycosylation of human papillomavirus type 16 L1 protein. Virology (1993) 0.87
Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem (1999) 0.86
Pathogen recognition and innate immunity. Cell (2006) 44.14
Toll-like receptor signalling. Nat Rev Immunol (2004) 34.74
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 26.12
Toll-like receptors. Annu Rev Immunol (2001) 26.06
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell (2009) 20.29
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 17.57
Induction of colonic regulatory T cells by indigenous Clostridium species. Science (2010) 16.71
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 16.26
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 11.39
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Innate immune recognition of viral infection. Nat Immunol (2006) 9.59
DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (2002) 9.40
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature (2004) 9.40
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol (2005) 9.17
TLR signaling pathways. Semin Immunol (2004) 9.08
Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med (2008) 9.00
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature (2007) 8.87
TLR signaling. Semin Immunol (2007) 8.16
ATP drives lamina propria T(H)17 cell differentiation. Nature (2008) 8.02
A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol (2005) 7.94
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol (2008) 7.87
Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature (2008) 7.64
ER stress triggers apoptosis by activating BH3-only protein Bim. Cell (2007) 7.50
Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med (2003) 7.38
Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol (2009) 7.35
Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med (2003) 7.26
Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 7.25
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol (2002) 7.07
Innate immunity to virus infection. Immunol Rev (2009) 7.04
Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol (2009) 6.62
Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med (2007) 6.52
Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest (2002) 6.48
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 6.47
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 6.40
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Intra-individual change over time in DNA methylation with familial clustering. JAMA (2008) 6.17
Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol (2005) 6.13
Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity (2006) 5.98
Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci (2008) 5.95
Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 5.76
Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol (2004) 5.71
Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A (2006) 5.70
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A (2004) 5.58
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev (2005) 5.56
Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol (2002) 5.48
Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol (2002) 5.41
Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med (2009) 5.25
The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 5.21
Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem (2006) 5.11
Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol (2008) 5.10
Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med (2006) 5.01
TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol (2003) 4.94
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol (2005) 4.91
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol (2005) 4.83
Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature (2002) 4.81
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol (2010) 4.66
TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity (2004) 4.50
Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc Natl Acad Sci U S A (2009) 4.48
Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature (2012) 4.46
Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol (2006) 4.37